Richmond Brothers Inc. Has $983,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Richmond Brothers Inc. increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 25.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 642,339 shares of the biotechnology company’s stock after buying an additional 131,557 shares during the quarter. Heron Therapeutics accounts for 0.6% of Richmond Brothers Inc.’s portfolio, making the stock its 22nd biggest holding. Richmond Brothers Inc. owned approximately 0.42% of Heron Therapeutics worth $983,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Clearline Capital LP lifted its stake in Heron Therapeutics by 48.9% during the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares during the period. Congress Park Capital LLC lifted its stake in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after purchasing an additional 477,417 shares during the period. XTX Topco Ltd lifted its stake in Heron Therapeutics by 449.0% during the third quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company’s stock worth $592,000 after purchasing an additional 243,363 shares during the period. CM Management LLC lifted its stake in Heron Therapeutics by 40.0% during the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company’s stock worth $1,071,000 after purchasing an additional 200,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Heron Therapeutics by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 154,487 shares during the period. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Trading Up 3.8 %

NASDAQ:HRTX opened at $2.48 on Wednesday. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93. The firm has a 50 day moving average of $1.87 and a 200-day moving average of $1.75. The stock has a market capitalization of $377.78 million, a P/E ratio of -13.78 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. As a group, analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on HRTX. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.